Gilead’s selonsertib fails to meet primary endpoint in Phase 3 NASH study
Stellar-3 is a randomized, double-blind and placebo-controlled trial, which assessed the safety and efficacy of selonsertib in patients with bridging fibrosis (F3) due to NASH. According to the